ReviewThrombosis and haemostasis2019
Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.
Review in Thrombosis and haemostasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Pharmacological Management of Thrombosis: Current State and Future Strategies.International journal of molecular sciences · 2026Review
- Freeze-Dried Platelet-Derived Hemostatic Products to Treat Bleeding in Dual Antiplatelet Therapy.JACC. Basic to translational science · 2025Article
- Impact of P2Y12 inhibitors on clinical outcomes in sepsis-3 patients receiving aspirin: a propensity score matched analysis.BMC infectious diseases · 2024Article
- Ticagrelor inverse agonist activity at the P2YBritish journal of pharmacology · 2024Article
- Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents.Circulation research · 2023Article
- Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review.International journal of environmental research and public health · 2020Review
Corrections and comments
- Erratum issuedErratum.2019
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are clinical scenarios where the balance between the risk of ischemic and bleeding events leads to the clinical decision to reverse the antiplatelet effect of P2Y
Indexed as
Identifiers
31408901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.